• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Aardvark Therapeutics Inc.

    2/24/25 5:55:38 PM ET
    $AARD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AARD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Aardvark Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share (the "Shares")

    (Title of Class of Securities)


    002942100

    (CUSIP Number)


    02/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,152,375.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,152,375.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,152,375.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 21,384,377 Shares outstanding as of February 14, 2025 (according to the issuer's prospectus as filed with the Securities and Exchange Commission on February 13, 2025). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on February 24, 2025.


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,152,375.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,152,375.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,152,375.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,152,375.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,152,375.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,152,375.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    40,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    40,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    40,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    40,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    40,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    40,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    40,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    40,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    40,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    002942100


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,192,971.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,192,971.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,192,971.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aardvark Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    4370 La Jolla Village Drive, Suite 1050 San Diego, CA, 92122
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share (the "Shares")
    (e)CUSIP No.:

    002942100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,152,375 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 40,596 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 40,596 Shares. 4. Mr. Griffin may be deemed to beneficially own 1,192,971 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 5.4% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 5.6% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,152,375 2. Citadel Securities LLC: 40,596 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 40,596 4. Mr. Griffin: 1,192,971

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,152,375 2. Citadel Securities LLC: 40,596 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 40,596 4. Mr. Griffin: 1,192,971

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/24/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/24/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/24/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/24/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/24/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/24/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:02/24/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $AARD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AARD

    DatePrice TargetRatingAnalyst
    3/10/2025$29.00Overweight
    Morgan Stanley
    3/10/2025$22.00Buy
    BofA Securities
    3/10/2025$50.00Overweight
    Cantor Fitzgerald
    3/10/2025$21.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $AARD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Decheng Capital Global Life Sciences Fund Iv, L.P. converted options into 2,667,299 shares and bought $20,000,000 worth of shares (1,250,000 units at $16.00) (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 5:44:41 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chi Jeffrey converted options into 133,364 shares (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 4:57:41 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Vickers Venture Fund Vi Pte Ltd converted options into 2,050,902 shares (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 4:48:42 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AARD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aardvark Therapeutics Inc.

      10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)

      5/14/25 4:50:30 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

      5/14/25 4:27:59 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Aardvark Therapeutics Inc.

      10-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

      3/31/25 4:45:05 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AARD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AARD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Morgan Stanley initiated coverage on Aardvark Therapeutics with a new price target

      Morgan Stanley initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $29.00

      3/10/25 7:14:54 AM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Aardvark Therapeutics with a new price target

      BofA Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $22.00

      3/10/25 7:14:38 AM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Aardvark Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $50.00

      3/10/25 7:14:28 AM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

      Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership team, including Timothy Kieffer, Ph.D., as Chief Scientific Officer; Danny Villeneuve as Chief Commercial Officer;

      5/19/25 4:10:00 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.

      5/14/25 4:10:00 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during May: Bank of America Global Healthcare Conference 2025 in Las VegasPresentation: Thursday, May 15 at 12:35 p.m. ET H.C. Wainwright 3rd Annual BioConnect Investor Conference in New YorkPresentation: Tuesday, May 20 at 3:30 p.m. ET 2025 RBC Capital Markets Global Healthcare Conference in New YorkPresentation: Wednesday, May 21 at 2:35 p.m. ET Live

      5/7/25 4:05:00 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AARD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Decheng Capital Global Life Sciences Fund Iv, L.P. converted options into 2,667,299 shares and bought $20,000,000 worth of shares (1,250,000 units at $16.00) (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 5:44:41 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Lee Tien-Li converted options into 41,303 shares and bought $264,672 worth of shares (16,542 units at $16.00), increasing direct ownership by 4% to 1,496,175 units (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 4:35:58 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sun Nelson converted options into 7,001 shares and bought $160,000 worth of shares (10,000 units at $16.00), increasing direct ownership by 21% to 99,484 units (SEC Form 4)

      4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

      2/19/25 4:30:49 PM ET
      $AARD
      Biotechnology: Pharmaceutical Preparations
      Health Care